NEUROCRINE BIOSCIENCES INC's ticker is and the CUSIP is 64125CAD1. A total of 59 filers reported holding NEUROCRINE BIOSCIENCES INC in Q1 2020. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2021 | $243,175,000 | -82.0% | 182,000 | -81.8% | 0.00% | -100.0% |
| Q1 2021 | $1,349,940,000 | -79.8% | 1,000,000 | -79.2% | 0.00% | -83.3% |
| Q4 2020 | $6,684,514,000 | -19.0% | 4,808,000 | -19.7% | 0.01% | 0.0% |
| Q3 2020 | $8,256,257,000 | +114.5% | 5,990,000 | +158.3% | 0.01% | +71.4% |
| Q2 2020 | $3,849,354,000 | -72.5% | 2,319,000 | -78.8% | 0.01% | -75.9% |
| Q1 2020 | $13,978,222,000 | +36.4% | 10,950,000 | +63.4% | 0.03% | +52.6% |
| Q4 2019 | $10,248,363,000 | +132.9% | 6,702,000 | +108.9% | 0.02% | +137.5% |
| Q3 2019 | $4,401,216,000 | -21.0% | 3,208,000 | -24.1% | 0.01% | -27.3% |
| Q2 2019 | $5,571,170,000 | -11.6% | 4,225,000 | -9.2% | 0.01% | -21.4% |
| Q1 2019 | $6,303,103,000 | +592.3% | 4,655,000 | +507.7% | 0.01% | +600.0% |
| Q4 2018 | $910,506,000 | +119.6% | 766,000 | +215.2% | 0.00% | +100.0% |
| Q3 2018 | $414,684,000 | +111.7% | 243,000 | +78.7% | 0.00% | – |
| Q2 2018 | $195,881,000 | – | 136,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aequim Alternative Investments LP | 24,000,000 | $30,877,000 | 5.11% |
| Alken Asset Management Ltd | 360,000 | $457,000 | 1.90% |
| III Capital Management | 3,500,000 | $4,481,000 | 1.64% |
| SHENKMAN CAPITAL MANAGEMENT INC | 3,920,000 | $5,113,000 | 0.76% |
| CSS LLC/IL | 6,842,000 | $8,745,000 | 0.69% |
| DeepCurrents Investment Group LLC | 10,408,000 | $13,373,000 | 0.65% |
| SSI INVESTMENT MANAGEMENT LLC | 4,334,000 | $5,554,000 | 0.49% |
| WOLVERINE ASSET MANAGEMENT LLC | 18,250,000 | $23,476,000 | 0.34% |
| MACKAY SHIELDS LLC | 24,612,000 | $31,641,000 | 0.29% |
| Nicholas Investment Partners, LP | 1,115,000 | $1,429,000 | 0.28% |